Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
…, H Aburatani, T Niki, Y Sohara, Y Sugiyama, H Mano - Nature, 2007 - nature.com
Improvement in the clinical outcome of lung cancer is likely to be achieved by identification
of the molecular events that underlie its pathogenesis. Here we show that a small inversion …
of the molecular events that underlie its pathogenesis. Here we show that a small inversion …
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
…, T Ueno, N Yamazaki, K Goto, M Tsuboi, H Mano… - Nature …, 2020 - nature.com
Immune checkpoint blockade has provided a paradigm shift in cancer therapy, but the success
of this approach is very variable; therefore, biomarkers predictive of clinical efficacy are …
of this approach is very variable; therefore, biomarkers predictive of clinical efficacy are …
Non‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer
H Mano - Cancer science, 2008 - Wiley Online Library
It is generally accepted that recurrent chromosome translocations play a major role in the
molecular pathogenesis of hematological malignancies but not of solid tumors. However, …
molecular pathogenesis of hematological malignancies but not of solid tumors. However, …
Tec family of protein-tyrosine kinases: an overview of their structure and function
H Mano - Cytokine & growth factor reviews, 1999 - Elsevier
The Tec family is a recently emerging subfamily of non-receptor protein-tyrosine kinases (PTKs)
represented by its first member, Tec. This family is composed of five members, namely …
represented by its first member, Tec. This family is composed of five members, namely …
RET, ROS1 and ALK fusions in lung cancer
…, Y Satoh, S Okumura, K Nakagawa, H Mano… - Nature medicine, 2012 - nature.com
Through an integrated molecular- and histopathology-based screening system, we performed
a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, …
a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, …
[HTML][HTML] EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
…, H Kimura, T Mitsudomi, Y Tanio, H Mano - … England Journal of …, 2010 - Mass Medical Soc
<p id="p001">The EML4 (echinoderm microtubule-associated protein-like 4)–ALK (anaplastic
lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non–…
lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non–…
ALKoma: a cancer subtype with a shared target
H Mano - Cancer discovery, 2012 - AACR
Anaplastic lymphoma kinase (ALK) is a receptor-type protein tyrosine kinase that is currently
the focus of much attention in oncology. ALK is rendered oncogenic as a result of its fusion …
the focus of much attention in oncology. ALK is rendered oncogenic as a result of its fusion …
[PDF][PDF] Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
The balance of programmed death-1 (PD-1)-expressing CD8 + T cells and regulatory T (Treg)
cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 …
cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 …
Oncogenic mutations of ALK kinase in neuroblastoma
…, T Igarashi, A Nakagawara, Y Hayashi, H Mano… - Nature, 2008 - nature.com
Neuroblastoma in advanced stages is one of the most intractable paediatric cancers, even
with recent therapeutic advances 1 . Neuroblastoma harbours a variety of genetic changes, …
with recent therapeutic advances 1 . Neuroblastoma harbours a variety of genetic changes, …
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer
…, S Okumura, K Nakagawa, Y Ishikawa, H Mano - Clinical Cancer …, 2009 - AACR
Purpose: EML4-ALK is a transforming fusion tyrosine kinase, several isoforms of which have
been identified in lung cancer. Immunohistochemical detection of EML4-ALK has proved …
been identified in lung cancer. Immunohistochemical detection of EML4-ALK has proved …